The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Linezolid versus Vancomycin for the Treatment of Methicillin‐Resistant Staphylococcus aureus Infections
Abstract
Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant strains. In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n=240) or vancomycin (1 g twice daily; n=220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA. Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection. At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiological success rates (58.9% in the linezolid group and 63.2% in the vancomycin group). Both regimens were well tolerated, with similar rates of adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Herold, B. C. (1998) · JAMA · doi:10.1001/jama.279.8.593 · Cited by 1,412
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Methicillin-ResistantStaphylococcus aureus in Europe
Voss, A., Milatovic, D., Wallrauch-Schwarz, C., Rosdahl, V. T., & Braveny, I. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02026127 · Cited by 801
Shlaes, D. M., Gerding, D. N., John, Jr., Craig, W. A., Bornstein, D. L., Duncan, R. A., Eckman, M. R., Farrer, W. E., Greene, W. H., Lorian, V., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/513766 · Cited by 780
Methicillin-Resistant Staphylococcus aureus in U.S. Hospitals, 1975–1991
Panlilio, A. L., Culver, D. H., Gaynes, R. P., Banerjee, S., Henderson, T. S., Tolson, J. S., Martone, W. J., & System, N. N. I. S. (1992) · Infection Control & Hospital Epidemiology · doi:10.1086/646432 · Cited by 657
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
(1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.282.12.1123 · Cited by 574
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
Rubin, R. J., Harrington, C. A., Poon, A., Dietrich, K., Greene, J. A., & Moiduddin, A. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0501.990102 · Cited by 445
Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/318486 · Cited by 440
Self-citationHealth and Economic Impacts of Antimicrobial Resistance
Holmberg, S. D., Solomon, S. L., & Blake, P. A. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.6.1065 · Cited by 413
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
Mortality Associated with Nosocomial Bacteremia Due to Methicillin-Resistant Staphylococcus aureus
Romero-Vivas, J., Rubio, M., Fernandez, C., & Picazo, J. J. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.6.1417 · Cited by 318
Abramson, M. A., & Sexton, D. J. (1999) · Infection Control & Hospital Epidemiology · doi:10.1086/501641 · Cited by 314
Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3408-3413.2000 · Cited by 242
Self-citationMethicillin-Resistant Staphylococcus aureus as a Community Organism
Moreno, F., Crisp, C., Jorgensen, J. H., & Patterson, J. E. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1308 · Cited by 239
Community Strain of Methicillin-Resistant Staphylococcus aureus Involved in a Hospital Outbreak
O’Brien, F. G., Pearman, J. W., Gracey, M., Riley, T. V., & Grubb, W. B. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.9.2858-2862.1999 · Cited by 213
The Evolving Epidemiology of Methicillin-Resistant Staphylococcus aureus at a University Hospital
Layton, M. C., Hierholzer, W. J., & Patterson, J. E. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/646996 · Cited by 203
Risk Factors for ICU-Acquired Pneumonia
Cook, D. J. (1998) · JAMA · doi:10.1001/jama.279.20.1605 · Cited by 190
Ariza, J., Pujol, M., Cabo, J., Peña, C., Fernández, N., Liñares, J., Ayats, J., & Gudiol, F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01017-x · Cited by 167
ANTIMICROBIAL RESISTANCE IN STAPHYLOCOCCI
Maranan, M. C., Moreira, B., Boyle-Vavra, S., & Daum, R. S. (1997) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70392-5 · Cited by 166
Bacteremia Caused by Staphylococci with Inducible Vancomycin Heteroresistance
Wong, S. S. Y., Ho, P. L., Woo, P. C. Y., & Yuen, K. Y. (1999) · Clinical Infectious Diseases · doi:10.1086/520429 · Cited by 165
The in-vitro activity of linezolid (U-100766) and tentative breakpoints
Wise, R. A., Andrews, J. M., Boswell, F. J., & Ashby, J. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.721 · Cited by 149
Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., & Kaatz, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.721 · Cited by 147
FRANK, A. L., MARCINAK, J. F., MANGAT, P. D., & Schreckenberger, P. C. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199911000-00012 · Cited by 147
Dresser, L., & Rybak, M. J. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03109.x · Cited by 143
Ford, C. W., Hamel, J. C., Wilson, D. M., Moerman, J. K., Stapert, D., Yancey, R. J., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1508 · Cited by 140
Jones, R. N., Kehrberg, E. N., Erwin, M. E., & Anderson, S. C. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90033-7 · Cited by 138
Linezolid absolute bioavailability and the effect of food on oral bioavailability
Welshman, I. R., Sisson, T. L., Jungbluth, G. L., Stalker, D. J., & Hopkins, N. K. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.255 · Cited by 133
Li, Z., Willke, R. J., Pinto, L. A., Rittenhouse, B., Rybak, M. J., Pleil, A. M., Crouch, C. W., Hafkin, B., & Glick, H. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.3.263.34198 · Cited by 130
Self-citationEmbil, J. M., Ramotar, K., Romance, L., Alfa, M. J., Conly, J. M., Cronk, S., Taylor, G., Sutherland, B., Louie, T., Henderson, E., et al. (1994) · Infection Control and Hospital Epidemiology · doi:10.1086/646827 · Cited by 126
Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
Matassova, N., Rodnina, M. V., Endermann, R., Kroll, H., Pleiß, U., Wild, H., & Wintermeyer, W. (1999) · RNA · doi:10.1017/s1355838299990210 · Cited by 75
Overview of Resistance in the 1990s
File, T. M. (1999) · CHEST Journal · doi:10.1378/chest.115.suppl_1.3s · Cited by 74
Jorgensen, J. H., McElmeel, M. L., & Trippy, C. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.465 · Cited by 71
Embil, J. M., Ramotar, K., Romance, L., Alfa, M. J., Conly, J. M., Cronk, S., Taylor, G., Sutherland, B., Louie, T., Henderson, E., et al. (1994) · Infection Control and Hospital Epidemiology · doi:10.2307/30145275 · Cited by 46
Community-acquired methicillin-resistant Staphylococcus aureus infections in children
Rathore, M. H., & Kline, M. W. (1989) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-198909000-00017 · Cited by 33
Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device-days
Bonten, M. J. M., & Weinstein, R. A. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00001 · Cited by 16
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Self-citationCommunity-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Metadata
- Authors
- Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-06
- Volume
- 34
- Issue
- 11
- Pages
- 1481-1490
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2276443311
- Cited by
- 506
- References
- 44
- FWCI
- 26.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.